Mostrar el registro sencillo

dc.contributor.authorFrutos, Fernando dees_ES
dc.contributor.authorOchoa, Juan Pabloes_ES
dc.contributor.authorNavarro-Peñalver, Marinaes_ES
dc.contributor.authorBaas, Annettees_ES
dc.contributor.authorVandborg, Bjerrees_ES
dc.contributor.authorZorio, Estheres_ES
dc.contributor.authorMéndez, Irenees_ES
dc.contributor.authorLorca, Rebecaes_ES
dc.contributor.authorVerdonschot, Job AJ.es_ES
dc.contributor.authorGarcía-Granja, Pablo Elpidioes_ES
dc.contributor.authorBilinska, Zofiaes_ES
dc.contributor.authorFatkin, Dianees_ES
dc.contributor.authorFuentes-Cañamero, M. Eugeniaes_ES
dc.contributor.authorGarcía-Pinilla, José M.es_ES
dc.contributor.authorGarcía-Álvarez, María I.es_ES
dc.contributor.authorGirolami, Francescaes_ES
dc.contributor.authorBarriales-Villa, Robertoes_ES
dc.contributor.authorDíez-López, Carleses_ES
dc.contributor.authorLopes, Luis R.es_ES
dc.contributor.authorRuiz Guerrero, Luis Javieres_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2023-02-24T15:14:38Z
dc.date.available2023-09-01T02:15:33Z
dc.date.issued2022-08-22es_ES
dc.identifier.issn0735-1097es_ES
dc.identifier.issn1558-3597es_ES
dc.identifier.urihttps://hdl.handle.net/10902/27869
dc.description.abstractBackground Variants in MYH7 are responsible for disease in 1-5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described. Objectives We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression. Methods We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% females, 35.6±19.2 years) recruited from 29 international centers. Results At initial evaluation, 106 patients (72.1%) had DCM (LVEF 34.5±11.7%). Median follow-up was 4.5 years (interquartile range: 1.7-8.0) and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years. Thirty-six percent of patients with DCM met imaging criteria for LV non-compaction. During follow-up, 28% showed left ventricular reverse remodeling (LVRR). Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths due to end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia (MVA) rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF?35%, respectively). ESHF and MVA were significantly lower compared with LMNA-related DCM and similar than in DCM caused by TTN truncating variants. Conclusions MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low LVRR, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare.es_ES
dc.description.sponsorshipFunding: This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects "PI18/0004, PI20/0320, PT17/0015/0043” (Co-funded by European Regional Development Fund/European Social Fund "A way to make Europe"/"Investing in your future"). The CNIC is supported by the ISCIII, MCIN, the Pro-CNIC Foundation, and the Severo Ochoa Centers of Excellence program (CEX2020-001041-S). The Hospital Universitario Puerta de Hierro, the Hospital Sant Joan de Déu and the Hospital Universitario Virgen de la Arrixaca are members of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart (http://guardheart.ernnet.eu). Fernando de Frutos receives grant support from ISCIII (CM20/00101). Annette Baas receives funding from CVON2020B005 DOUBLE-DOSE, Dutch Heart Foundation (Dekker 2015T041). Genetic examinations of Polish patients were funded with DETECTIN-HF grant from ERA-CVD framework, NCBiR. Diane Fatkin receives funding from Victor Chang Cardiac Research Institute and NSW Health. Luis R Lopes is funded by an MRC UK Clinical Academic Research Partnership award (MR/T005181/1). Benjamin Meder receives funding from the Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research, DZHK) and Informatics for Life (Klaus Tschira Foundation). Milos Kubankek receives grant support from the Ministry of Health, Czech Republic (NV19-08-00122) and IPO (Institute for Clinical and Experimental Medicine – IKEM, IN 00023001).es_ES
dc.format.extent43 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© 2022 The authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY -NC-ND license*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceJournal of the American College of Cardiology, 2022, 80 (15) 1447–1461es_ES
dc.subject.otherMYH7es_ES
dc.subject.otherDilated cardiomyopathyes_ES
dc.subject.otherGeneticses_ES
dc.titleNatural History of MYH7-related Dilated Cardiomyopathyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.jacc.2022.07.023es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1016/j.jacc.2022.07.023es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2022 The authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY -NC-ND licenseExcepto si se señala otra cosa, la licencia del ítem se describe como © 2022 The authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY -NC-ND license